Jefferies analyst Michael Yee last night upgraded Esperion Therapeutics to Buy from Hold and raised his price target for the shares to $85 from $55. The shares are likely "to keep grinding higher and higher" following the "new de-risking data" for the triple combination, Yee tells investors in a research note. The analyst sees potential partnership opportunities as a "big catalyst."
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here